#United States #Washington D.C. #ophthalmology #Viatris #ASCRS

Viatris at the ASCRS Annual Meeting 2026

Viatris Inc., a significant player in the global healthcare sector, is set to impress with a series of data presentations at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. Scheduled for April 10-13, 2026, in Washington, D.C., Viatris will present four abstracts highlighting innovative research in ophthalmology.

Key Presentations

1. VEGA-3 Study Results

One of the highlights will be the full results from the VEGA-3 Phase 3 study focusing on MR-141, an ophthalmic solution aimed at addressing presbyopia, a common vision condition associated with aging. This study is critical, as it looks to provide new options for the millions who experience diminished near-vision capabilities.

2. Varenicline Solution Nasal Spray Study

In another promising study, Viatris will present findings from a Phase 1 trial exploring the effects of a varenicline solution nasal spray administered to healthy adult volunteers in Japan. This research could open new avenues in ophthalmological treatments.

3. MIRA-2 Post-Hoc Analysis

Additionally, a post-hoc analysis of the MIRA-2 study will discuss the optical impact of RYZUMVI®, specifically in reversing mydriasis induced pharmacologically. This analysis is particularly important for understanding how such treatments can improve visual quality post-procedure.

4. LYNX-2 Encore Presentation

Viatris will also reintroduce data from LYNX-2, assessing MR-142 for visual disturbances caused by low light conditions in patients who have undergone refractive surgery, which remains a major consideration for those affected by surgery-induced visual impairments.

All these presentations underscore Viatris's commitment to pushing the frontiers in eye care and management of common vision issues.

Educational Symposium

Complementing its primary presentations, Viatris is sponsoring an independent educational symposium titled "Presbyopia Re-Envisioned: A New Era of Pharmacological Vision Correction". Scheduled for April 11 at the Westin DC Downtown, this event aims to enhance peer-to-peer exchanges and support clinicians engaging with the evolving landscape of presbyopia management.

Importance of Addressing Presbyopia

Presbyopia, affecting nearly 128 million individuals in the United States, is characterized by a progressive loss of the ability to focus on close objects, which generally becomes noticeable in a person's 40s. This increasingly common condition significantly hampers daily functionality. Addressing presbyopia not only improves quality of life but also aids in maintaining productivity in an aging population.

Viatris’s efforts highlight the critical need for innovative solutions in the ophthalmic field. With an extensive history of focusing on unmet health needs, the company is committed to delivering improvements that meet the needs of healthcare providers and patients alike.

The ASCRS meeting is an essential platform for Viatris, presenting opportunities for networking with peers and discussions on innovative study outcomes. Attendees can find Viatris at booth #233, where they can learn more about the presented data and the future direction of ophthalmological treatments.

In conclusion, these presentations reaffirm Viatris's pivotal role in advancing healthcare solutions that cater to worldwide visual health needs and represent the company’s ongoing dedication to improving the lives of those affected by presbyopia and other vision impairments.